ZEVALIN Side Effects

7018362-8 | Bone Marrow Failure, Liver Function Test Abnormal
on Sep 08, 2010 Male patient from JAPAN , 71 years of age, was diagnosed with mantle cell lymphoma stage iv and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure, liver function test abnormal. Zevalin dosage: 863 Mbq;1x;iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), IBRUPROFEN (View Ibruprofen Review and Ibruprofen Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), DIOVAN (View Diovan Review and Diovan Label ), CALSLOT (View Calslot Review and Calslot Label ), BAKTAR (View Baktar Review and Baktar Label ).

6985233-2 | Hepatic Steatosis, Liver Disorder, Platelet Count Decreased, White Blood Cell Count Decreased
Patient was taking Zevalin (View Usage). Patient had the following side effects: hepatic steatosis, liver disorder, platelet count decreased, white blood cell count decreased on Aug 26, 2010 from JAPAN Additional patient health information: Male patient , 42 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage i and. Zevalin dosage: 1413 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), URSO 250 (View Urso 250 Review and Urso 250 Label ), SOLU CORTEF (View Solu-cortef Review and Solu-cortef Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6946239-2 | Haematotoxicity, Leukaemia, Lung Infection Pseudomonal, Neutropenia, Pneumonia Bacterial, Thrombocytopenia
Adverse event was reported on Aug 09, 2010 by a Male patient taking Zevalin (View Usage) (Dosage: 1.2 Mci/kg; Ix; Iv) was diagnosed with diffuse large b-cell lymphoma, stem cell transplant and. Location: UNITED STATES , 55 years of age, After Zevalin was administered, patient had the following side effects: haematotoxicity, leukaemia, lung infection pseudomonal, neutropenia, pneumonia bacterial, thrombocytopenia. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ).

6944638-6 | Acute Graft Versus Host Disease In Intestine
on Aug 13, 2010 Male patient from SPAIN , 60 years of age, weighting 121.3 lb, was diagnosed with b-cell lymphoma, prophylaxis against graft versus host disease, antifungal prophylaxis, antiviral prophylaxis and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine. Zevalin dosage: . During the same period patient was treated with YTRACIS (View Ytracis Review and Ytracis Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), MELFALAN (View Melfalan Review and Melfalan Label ), CICLOSPORIN 50 MG (Total Daily Dose: 100 Mg) (View Ciclosporin 50 Mg Review and Ciclosporin 50 Mg Label ), POSACONAZOLE (Total Daily Dose: 600 Mg) (View Posaconazole Review and Posaconazole Label ), VALGANCICLOVIR (As Used: 900 Mg) (View Valganciclovir Review and Valganciclovir Label ). Patient was hospitalized.


6929709-2 | Demyelination, Paraesthesia
on Jul 29, 2010 Male patient from SPAIN , 49 years of age, was diagnosed with b-cell lymphoma and was treated with Zevalin (View Usage). Patient had the following side effects: demyelination, paraesthesia. Zevalin dosage: 1x;iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6929705-5 | Pyrexia
Patient was taking Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: pyrexia on Jul 28, 2010 from FRANCE Additional patient health information: Female patient , 74 years of age, was diagnosed with non-hodgkin's lymphoma and. Zevalin dosage: 783 Mbq;1x;iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

6928087-2 | Acute Graft Versus Host Disease In Skin, Diarrhoea, Nausea, Stem Cell Transplant
Adverse event was reported on Jul 27, 2010 by a Female patient taking Zevalin (View Usage) (Dosage: 0.4 Mci/kg; 1x;iv) was diagnosed with non-hodgkin's lymphoma recurrent, stem cell transplant and. Location: FRANCE , 35 years of age, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, diarrhoea, nausea (What is nausea?), stem cell transplant. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), THYMOGLOBULIN (View Thymoglobulin Review and Thymoglobulin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6928086-0 | Bone Marrow Failure, Chills, Erythema, Gastrointestinal Disorder, Hyperthermia, Neutropenia
on Jul 27, 2010 Male patient from FRANCE , 58 years of age, was diagnosed with stem cell transplant and was treated with Zevalin (View Usage). Patient had the following side effects: bone marrow failure, chills, erythema, gastrointestinal disorder, hyperthermia, neutropenia. Zevalin dosage: 0.4 Mci/kg;1x;iv. During the same period patient was treated with AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ), BACTRIM (View Bactrim Review and Bactrim Label ), ZELITREX (View Zelitrex Review and Zelitrex Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), BUSUKLFAN (View Busuklfan Review and Busuklfan Label ), THYMOGLOBULIN (View Thymoglobulin Review and Thymoglobulin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6928085-9 | Anaemia, Asthenia, Pyrexia
on Jul 27, 2010 Female patient from FRANCE , 33 years of age, was diagnosed with non-hodgkin's lymphoma recurrent, stem cell transplant and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: anaemia, asthenia, pyrexia. Zevalin dosage: 0.4 Mci/kg;iv. Patient was hospitalized.

6916366-4 | Haematotoxicity, Leukopenia, Neutropenia, Thrombocytopenia, Upper Respiratory Tract Inflammation
Patient was taking Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: haematotoxicity, leukopenia, neutropenia, thrombocytopenia, upper respiratory tract inflammation on Jul 21, 2010 from JAPAN Additional patient health information: Female patient , 61 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage iii and. Zevalin dosage: 511 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), COTRIM (View Cotrim Review and Cotrim Label ), ZYLORIC (View Zyloric Review and Zyloric Label ), GASTER D (View Gaster D Review and Gaster D Label ), ANTIPYRETICS (View Antipyretics Review and Antipyretics Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), MAGMITT (View Magmitt Review and Magmitt Label ). Patient was hospitalized.

6883777-5 | Herpes Oesophagitis
Adverse event was reported on Jul 12, 2010 by a Female patient taking Zevalin (View Usage) (Dosage: 847 Mbq; 1x; Iv) was diagnosed with b-cell lymphoma and. Location: BELGIUM , 60 years of age, Patient had the following side effects: herpes oesophagitis. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883775-1 | Aplasia, Aspergillus Test Positive, Athetosis, Chorea, Dermatitis Exfoliative, Infection, Lung Infection, Mononucleosis Syndrome
on Jul 12, 2010 Male patient from FRANCE , 52 years of age, was diagnosed with b-cell lymphoma and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: aplasia, aspergillus test positive, athetosis, chorea, dermatitis exfoliative, infection (What is infection?), lung infection, mononucleosis syndrome. Zevalin dosage: 915 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883764-7 | Aplasia, Cholestasis, Cytolytic Hepatitis, Hilar Lymphadenopathy, Lymphadenopathy Mediastinal, Pleural Effusion, Pneumonia
on Jul 12, 2010 Female patient from FRANCE , 51 years of age, was diagnosed with b-cell lymphoma and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: aplasia, cholestasis, cytolytic hepatitis, hilar lymphadenopathy, lymphadenopathy mediastinal, pleural effusion, pneumonia (What is pneumonia?). Zevalin dosage: 1065 Mbq; Ix; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883695-2 | Cough, Engraftment Syndrome, Febrile Neutropenia, Infection, Lung Disorder, Lung Infiltration
Patient was taking Zevalin (View Usage). Patient had the following side effects: cough, engraftment syndrome, febrile neutropenia, infection (What is infection?), lung disorder, lung infiltration on Jul 12, 2010 from SWITZERLAND Additional patient health information: Female patient , 32 years of age, was diagnosed with b-cell lymphoma and. Zevalin dosage: 795 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883629-0 | Aspergillosis, Chest Pain, Lung Disorder
Adverse event was reported on Jul 12, 2010 by a Female patient taking Zevalin (View Usage) (Dosage: 820 Mbq; 1x; Iv) was diagnosed with b-cell lymphoma and. Location: FRANCE , 40 years of age, After Zevalin was administered, patient had the following side effects: aspergillosis, chest pain (What is chest pain?), lung disorder. During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), BICNU (View Bicnu Review and Bicnu Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883594-6 | Herpes Virus Infection, Stem Cell Transplant
on Jul 12, 2010 Female patient from FRANCE , 40 years of age, was diagnosed with b-cell lymphoma and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: herpes virus infection, stem cell transplant. Zevalin dosage: 22.4 Mci; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883511-9 | Herpes Zoster
on Jul 12, 2010 Male patient from BELGIUM , 62 years of age, was diagnosed with b-cell lymphoma, stem cell transplant and was treated with Zevalin (View Usage). Patient had the following side effects: herpes zoster. Zevalin dosage: 31.1 Mci; 1x;iv. During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), MELPHALAN (View Melphalan Review and Melphalan Label ). Patient was hospitalized.

6883507-7 | Haematotoxicity, Leukopenia, Neutropenia, Thrombocytopenia, Upper Respiratory Tract Inflammation
Patient was taking Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: haematotoxicity, leukopenia, neutropenia, thrombocytopenia, upper respiratory tract inflammation on Jul 14, 2010 from JAPAN Additional patient health information: Female patient , 61 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage iii and. Zevalin dosage: 511 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), COTRIM (View Cotrim Review and Cotrim Label ), ZYLORIC (View Zyloric Review and Zyloric Label ), GASTER D (View Gaster D Review and Gaster D Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), MAGMITT (View Magmitt Review and Magmitt Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6883482-5 | Aspiration, Enterocolitis, Lung Disorder, Neutropenia, Respiratory Failure
Adverse event was reported on Jul 12, 2010 by a Male patient taking Zevalin (View Usage) (Dosage: 1230 Mbq; 1x; Iv) was diagnosed with b-cell lymphoma and. Location: FRANCE , 47 years of age, Patient experienced the following unwanted or unexpected effects: aspiration, enterocolitis, lung disorder, neutropenia, respiratory failure. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ). Patient was hospitalized.

6883455-2 | Bone Marrow Failure
on Jul 13, 2010 Male patient from JAPAN , 53 years of age, was diagnosed with extranodal marginal zone b-cell lymphoma (malt type) stage ii and was treated with Zevalin (View Usage). Patient had the following side effects: bone marrow failure. Zevalin dosage: 1362 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), LOXONIN (View Loxonin Review and Loxonin Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), FLUDEOXYGLUCOSE (View Fludeoxyglucose Review and Fludeoxyglucose Label ).

6883452-7 | Musculoskeletal Pain, Myopericarditis, Pericardial Effusion, Renal Failure, Tachycardia, Viral Infection
on Jul 12, 2010 Male patient from FRANCE , 60 years of age, was diagnosed with b-cell lymphoma and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: musculoskeletal pain, myopericarditis, pericardial effusion, renal failure, tachycardia, viral infection (What is viral infection?). Zevalin dosage: 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ). Patient was hospitalized.

6883451-5 | Candidiasis, Enterocolitis, Respiratory Failure
Patient was taking Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: candidiasis, enterocolitis, respiratory failure on Jul 12, 2010 from FRANCE Additional patient health information: Male patient , 47 years of age, was diagnosed with b-cell lymphoma and. Zevalin dosage: 3.2 Mci; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ). Patient was hospitalized.

6861459-3 | Anaemia, Condition Aggravated, Neutrophil Count Decreased, Platelet Count Decreased, Sinusitis
Adverse event was reported on Jun 30, 2010 by a Male patient taking Zevalin (View Usage) (Dosage: 932 Mbq;qm;iv) was diagnosed with b-cell small lymphocytic lymphoma stage iv and. Location: JAPAN , 68 years of age, Patient had the following side effects: anaemia, condition aggravated, neutrophil count decreased, platelet count decreased, sinusitis (What is sinusitis?). During the same period patient was treated with RITUXAN (CON.) (View Rituxan (con.) Review and Rituxan (con.) Label ), LOXONIN (CON.) (View Loxonin (con.) Review and Loxonin (con.) Label ), POLARAMINE (CON.) (View Polaramine (con.) Review and Polaramine (con.) Label ), MYSLEE (CON.) (View Myslee (con.) Review and Myslee (con.) Label ), VFEND (CON.) (View Vfend (con.) Review and Vfend (con.) Label ), OLMETEC (CON.) (View Olmetec (con.) Review and Olmetec (con.) Label ), MAGNESIUM OXIDE (CON.) (View Magnesium Oxide (con.) Review and Magnesium Oxide (con.) Label ), FLUITRAN (CON.) (View Fluitran (con.) Review and Fluitran (con.) Label ). Patient was hospitalized.

6861292-2 | Bone Marrow Failure
on Jun 30, 2010 Male patient from JAPAN , 73 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage iv and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: bone marrow failure. Zevalin dosage: 896 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), LOXONIN (View Loxonin Review and Loxonin Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), CIPROFLOXACIN HCL (View Ciprofloxacin Hcl Review and Ciprofloxacin Hcl Label ), STRONGER NEO MINOPHAGEN C P (View Stronger Neo-minophagen C P Review and Stronger Neo-minophagen C P Label ), FLUDEOXYGLUCOSE (View Fludeoxyglucose Review and Fludeoxyglucose Label ). Patient was hospitalized.

6861291-0 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Chest Pain, Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Recurrent, Liver Disorder, Pneumonia
on Jun 30, 2010 Female patient from JAPAN , 58 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, chest pain (What is chest pain?), follicle centre lymphoma, follicular grade i, ii, iii recurrent, liver disorder, pneumonia (What is pneumonia?). Zevalin dosage: 762 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), LOXONIN (View Loxonin Review and Loxonin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6843035-1 | Uterine Cancer
Patient was taking Zevalin (View Usage). Patient had the following side effects: uterine cancer (What is uterine cancer?) on Jun 24, 2010 from SPAIN Additional patient health information: Female patient , 67 years of age, was diagnosed with mantle cell lymphoma and. Zevalin dosage: Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), DEXAMETHASONS (View Dexamethasons Review and Dexamethasons Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6841791-X | Infection, Multi-organ Failure
Adverse event was reported on Jun 24, 2010 by a Male patient taking Zevalin (View Usage) (Dosage: 0.4 Mci/kg; 1x; Iv) was diagnosed with non-hodgkin's lymphoma recurrent, stem cell transplant and. Location: FRANCE , 63 years of age, After Zevalin was administered, patient had the following side effects: infection (What is infection?), multi-organ failure. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), THYMOGLOBULIN (View Thymoglobulin Review and Thymoglobulin Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYCLOSPORINE A (View Cyclosporine A Review and Cyclosporine A Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ).

6831730-X | Cystitis Haemorrhagic
on Jun 18, 2010 Male patient from JAPAN , 55 years of age, was diagnosed with extranodal marginal zone b-cell lymphoma (malt type) stage iii and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: cystitis haemorrhagic. Zevalin dosage: 965 Mbq, 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), ANTHIHISTAMINES (View Anthihistamines Review and Anthihistamines Label ), FLUDARA (View Fludara Review and Fludara Label ). Patient was hospitalized.

6814418-0 | Lymphoma, Myelodysplastic Syndrome
on Jun 14, 2010 Male patient from UNITED STATES , 59 years of age, was treated with Zevalin (View Usage). Patient had the following side effects: lymphoma (What is lymphoma?), myelodysplastic syndrome. Zevalin dosage: Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ).

6809285-5 | Multi-organ Failure
Patient was taking Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: multi-organ failure on Jun 24, 2010 from FRANCE Additional patient health information: Male patient , 63 years of age, weighting 160.9 lb, was diagnosed with non-hodgkin's lymphoma recurrent, stem cell transplant, prophylaxis against graft versus host disease and. Zevalin dosage: Total Daily Dose: 0.4 Mci/kg. During the same period patient was treated with YTRACIS (Total Daily Dose: 0.4 Mci/kg) (View Ytracis Review and Ytracis Label ), RITUXIMAB (On Day-14) (View Rituximab Review and Rituximab Label ), FLUDARABINE (On Days -6 To -2) (View Fludarabine Review and Fludarabine Label ), THYMOGLOBULIN (On Day-4) (View Thymoglobulin Review and Thymoglobulin Label ), BUSULFAN (On Days -5 And -4) (View Busulfan Review and Busulfan Label ), CYCLOSPORINE (2 To 3 Mg/kg From Day-1) (View Cyclosporine Review and Cyclosporine Label ).

6800999-X | Aphasia, Cerebral Haemorrhage, Hemiplegia
Adverse event was reported on Jun 09, 2010 by a Male patient taking Zevalin (View Usage) (Dosage: ; 1x; Iv) was diagnosed with non-hodgkin's lymphoma, stem cell transplant and. Location: GERMANY , 48 years of age, Patient experienced the following unwanted or unexpected effects: aphasia (What is aphasia?), cerebral haemorrhage, hemiplegia. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ). Patient was hospitalized.

6800998-8 | Acute Respiratory Distress Syndrome, Interstitial Lung Disease, Multi-organ Failure, Pulmonary Fibrosis
on Jun 09, 2010 Female patient from KOREA, REPUBLIC OF , 36 years of age, was diagnosed with diffuse large b-cell lymphoma recurrent and was treated with Zevalin (View Usage). Patient had the following side effects: acute respiratory distress syndrome, interstitial lung disease, multi-organ failure, pulmonary fibrosis (What is pulmonary fibrosis?). Zevalin dosage: 0.4 Mci/kg; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6798227-7 | Anuria, Intestinal Perforation, Neoplasm Progression, Peritonitis, Platelet Count Decreased, Septic Shock, White Blood Cell Count Decreased
on Jun 08, 2010 Female patient from JAPAN , 68 years of age, was diagnosed with mantle cell lymphoma stage iii and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: anuria, intestinal perforation, neoplasm progression, peritonitis, platelet count decreased, septic shock, white blood cell count decreased. Zevalin dosage: 130 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

6784459-0 | Diffuse Large B-cell Lymphoma, Exophthalmos, Haemorrhagic Tumour Necrosis, Inflammation, Parophthalmia
Patient was taking Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: diffuse large b-cell lymphoma, exophthalmos, haemorrhagic tumour necrosis, inflammation, parophthalmia on Jun 01, 2010 from UNITED STATES Additional patient health information: Male patient , 64 years of age, was diagnosed with diffuse large b-cell lymphoma and. Zevalin dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), ANTHRACYCLINE (View Anthracycline Review and Anthracycline Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), ANTIFOLATE AGONIST PRALATREXATE (View Antifolate Agonist Pralatrexate Review and Antifolate Agonist Pralatrexate Label ), BENDAMUSTINE (View Bendamustine Review and Bendamustine Label ).

6772549-8 | Acute Respiratory Distress Syndrome, Interstitial Lung Disease, Multi-organ Failure, Pulmonary Fibrosis
Adverse event was reported on May 28, 2010 by a Female patient taking Zevalin (View Usage) (Dosage: 0.4 Mci/kg;1x;iv) was diagnosed with diffuse large b-cell lymphoma recurrent and. Location: KOREA, REPUBLIC OF , 30 years of age, Patient had the following side effects: acute respiratory distress syndrome, interstitial lung disease, multi-organ failure, pulmonary fibrosis (What is pulmonary fibrosis?). During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6750986-5 | Blood Urea Increased, C-reactive Protein Increased, Neutrophil Count Decreased, Pancytopenia, Platelet Count Decreased
on May 11, 2010 Male patient from JAPAN , 79 years of age, was diagnosed with mantle cell lymphoma stage i and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: blood urea increased, c-reactive protein increased, neutrophil count decreased, pancytopenia, platelet count decreased. Zevalin dosage: 974 Mbq; 1x ;iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), ANALGESICS (View Analgesics Review and Analgesics Label ), ANTIPYRETICS (View Antipyretics Review and Antipyretics Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), ALLEGRA (View Allegra Review and Allegra Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), CONIEL (View Coniel Review and Coniel Label ), MAGLAX (View Maglax Review and Maglax Label ). Patient was hospitalized.

6750625-3 | Acute Graft Versus Host Disease In Intestine, Gastroenteritis Norovirus, Pneumonia, Septic Shock, Stem Cell Transplant
on May 13, 2010 Male patient from CANADA , 64 years of age, was diagnosed with b-cell lymphoma, stem cell transplant and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, gastroenteritis norovirus, pneumonia (What is pneumonia?), septic shock, stem cell transplant. Zevalin dosage: 32 Mci; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), SEPTRA DS (View Septra Ds Review and Septra Ds Label ), ADALAT CC (View Adalat Cc Review and Adalat Cc Label ), ZANTAC (View Zantac Review and Zantac Label ). Patient was hospitalized.

6731883-8 | Lymphoma, Myelodysplastic Syndrome
Patient was taking Zevalin (View Usage). Patient had the following side effects: lymphoma (What is lymphoma?), myelodysplastic syndrome on Apr 29, 2010 from UNITED STATES Additional patient health information: Male patient , 59 years of age, . Zevalin dosage: Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), PREV MEDS (View Prev Meds Review and Prev Meds Label ).

6730828-4 | Melaena, Neutrophil Count Decreased, Nystagmus, Pseudomembranous Colitis, Vertigo Positional, White Blood Cell Count Decreased
Adverse event was reported on Apr 28, 2010 by a Male patient taking Zevalin (View Usage) (Dosage: 833 Mbq; 1x; Iv) was diagnosed with mantle cell lymphoma and. Location: JAPAN , 64 years of age, After Zevalin was administered, patient had the following side effects: melaena, neutrophil count decreased, nystagmus, pseudomembranous colitis, vertigo positional, white blood cell count decreased. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), GASTER D (View Gaster D Review and Gaster D Label ), METHYLCOBAL (View Methylcobal Review and Methylcobal Label ), ENTERONON R (View Enteronon R Review and Enteronon R Label ), NEUFAN (View Neufan Review and Neufan Label ), AMLODIN OD (View Amlodin Od Review and Amlodin Od Label ), GOSHAJINKIGAN (View Goshajinkigan Review and Goshajinkigan Label ), ITRIZOLE (View Itrizole Review and Itrizole Label ). Patient was hospitalized.

6727654-9 | Hepatic Function Abnormal, Pancytopenia
on Oct 14, 2009 Male patient from JAPAN , 43 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal, pancytopenia. Zevalin dosage: 13.2 Mbq/kg;1x;iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), AMARYL (View Amaryl Review and Amaryl Label ), VOGIBOSE (View Vogibose Review and Vogibose Label ), LIPITOR (View Lipitor Review and Lipitor Label ), ULCERLMIN (View Ulcerlmin Review and Ulcerlmin Label ), SOTIUM BICARBONATE (View Sotium Bicarbonate Review and Sotium Bicarbonate Label ), ALSOITOL (View Alsoitol Review and Alsoitol Label ), ANALGESICS (View Analgesics Review and Analgesics Label ).

6692537-X | Cystitis Haemorrhagic
on Apr 02, 2010 Male patient from JAPAN , 60 years of age, was diagnosed with extranodal marginal zone b-cell lymphoma (malt type) stage iii and was treated with Zevalin (View Usage). Patient had the following side effects: cystitis haemorrhagic. Zevalin dosage: 965 Mbq; 1x; Iv. During the same period patient was treated with RITUIXIMAB (View Rituiximab Review and Rituiximab Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUDARA (View Fludara Review and Fludara Label ). Patient was hospitalized.

6689331-2 | Bronchopulmonary Aspergillosis, Febrile Neutropenia, Immune Reconstitution Syndrome
Patient was taking Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: bronchopulmonary aspergillosis, febrile neutropenia, immune reconstitution syndrome on Apr 02, 2010 from ITALY Additional patient health information: Male patient , 64 years of age, was diagnosed with non-hodgkin's lymphoma and. Zevalin dosage: 1.2 Mci/kg; Iv. During the same period patient was treated with CON MEDS (View Con Meds Review and Con Meds Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ). Patient was hospitalized.

6680303-0 | Leukopenia, Neutropenia, Thrombocytopenia, Upper Respiratory Tract Inflammation
Adverse event was reported on Mar 25, 2010 by a Female patient taking Zevalin (View Usage) (Dosage: 511 Mbq; 1x; Iv) was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage i and. Location: JAPAN , 61 years of age, Patient experienced the following unwanted or unexpected effects: leukopenia, neutropenia, thrombocytopenia, upper respiratory tract inflammation. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), COTRIM (View Cotrim Review and Cotrim Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), GASTER D (View Gaster D Review and Gaster D Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), MAGMITT (View Magmitt Review and Magmitt Label ). Patient was hospitalized.

6666807-5 | Anaemia, Clostridium Difficile Colitis, Febrile Neutropenia, Stomatitis, Thrombocytopenia
on Mar 16, 2010 Female patient from FRANCE , 67 years of age, was diagnosed with non-hodgkin's lymphoma recurrent and was treated with Zevalin (View Usage). Patient had the following side effects: anaemia, clostridium difficile colitis, febrile neutropenia, stomatitis, thrombocytopenia. Zevalin dosage: 802 Mbq;1x;iv. During the same period patient was treated with RITUXIMAB (CON.) (View Rituximab (con.) Review and Rituximab (con.) Label ), CARMUSTINE (CON.) (View Carmustine (con.) Review and Carmustine (con.) Label ), CYTOSINE (View Cytosine Review and Cytosine Label ), ARABINOSIDE (CON.) (View Arabinoside (con.) Review and Arabinoside (con.) Label ), ETOPOSIDE (CON.) (View Etoposide (con.) Review and Etoposide (con.) Label ), MELPHALAN (CON.) (View Melphalan (con.) Review and Melphalan (con.) Label ). Patient was hospitalized.

6659716-9 | Bone Marrow Failure, Nausea
on Mar 10, 2010 Male patient from JAPAN , 52 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: bone marrow failure, nausea (What is nausea?). Zevalin dosage: 796 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), LOXONIN (View Loxonin Review and Loxonin Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), CRAVIT (View Cravit Review and Cravit Label ), LECICARBON (View Lecicarbon Review and Lecicarbon Label ), FLUDARA (View Fludara Review and Fludara Label ). Patient was hospitalized.

6659715-7 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Liver Disorder, Pneumonia
Patient was taking Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, liver disorder, pneumonia (What is pneumonia?) on Mar 10, 2010 from JAPAN Additional patient health information: Female patient , 58 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage i and. Zevalin dosage: 762 Mbq; 1x; Iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), LOXONIN (View Loxonin Review and Loxonin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6658769-1 | Abdominal Pain Upper, Bone Marrow Failure, Neuropathy Peripheral
Adverse event was reported on Mar 10, 2010 by a Female patient taking Zevalin (View Usage) (Dosage: 740 Mbq; 1x; Iv) was diagnosed with extranodal marginal zone b-cell lymphoma (malt type) stage ii and. Location: JAPAN , 71 years of age, Patient had the following side effects: abdominal pain upper, bone marrow failure, neuropathy peripheral. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), LOXONIN (View Loxonin Review and Loxonin Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), LENDORMIN (View Lendormin Review and Lendormin Label ), CONSTAN (View Constan Review and Constan Label ), MYSLEE (View Myslee Review and Myslee Label ), SOLANAX (View Solanax Review and Solanax Label ), ADALAT CC (View Adalat Cc Review and Adalat Cc Label ). Patient was hospitalized.

6658759-9 | Bone Marrow Failure, Coma, Condition Aggravated, Nasopharyngitis, Pneumonia, Pseudomonas Infection, Septic Shock, Sinusitis
on Mar 10, 2010 Male patient from JAPAN , 65 years of age, was diagnosed with b-cell lymphoma and was treated with Zevalin (View Usage). After Zevalin was administered, patient had the following side effects: bone marrow failure, coma, condition aggravated, nasopharyngitis, pneumonia (What is pneumonia?), pseudomonas infection, septic shock, sinusitis (What is sinusitis?). Zevalin dosage: 630 Mbq; 1x; Iv. During the same period patient was treated with RITUXAN (View Rituxan Review and Rituxan Label ), LOXONIN (View Loxonin Review and Loxonin Label ), COTRIM (View Cotrim Review and Cotrim Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUDARA (View Fludara Review and Fludara Label ), FLUDEOXYGLUCOSE (View Fludeoxyglucose Review and Fludeoxyglucose Label ). Patient was hospitalized.

6648327-7 | Intestinal Perforation, Mantle Cell Lymphoma, Neoplasm Progression, Peritonitis, Platelet Count Decreased, Septic Shock, White Blood Cell Count Decreased
on Mar 03, 2010 Female patient from JAPAN , 68 years of age, was diagnosed with mantle cell lymphoma stage iii and was treated with Zevalin (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal perforation, mantle cell lymphoma, neoplasm progression, peritonitis, platelet count decreased, septic shock, white blood cell count decreased. Zevalin dosage: 130 Mbq;1x;iv. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), ANTIHISTAMINES (View Antihistamines Review and Antihistamines Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

6647733-4 | Dyspnoea At Rest
Patient was taking Zevalin (View Usage). Patient had the following side effects: dyspnoea at rest on Feb 02, 2010 from SPAIN Additional patient health information: Female patient , 68 years of age, was diagnosed with mantle cell lymphoma and. Zevalin dosage: 16.5 Mci;iv. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.